Indian Pharmacopoeia Commission (IPC)

Mandate & Institutional Role

The IPC is an autonomous institution under India’s Ministry of Health & Family Welfare, tasked with developing and updating official drug standards through the Indian Pharmacopoeia (IP). This includes defining identity, purity, strength, and proper therapeutic usage of medicines and medical devices in India 

Core Functions

• Indian Pharmacopoeia (IP): A legally enforceable compendium of drug monographs and general quality standards, updated periodically based on emerging diseases and innovations 
• National Formulary of India (NFI): Supports rational prescription and use of generics, promoting cost-effective medicine use among healthcare professionals 
• Reference Substances (IPRS): IPC produces certified substances used as analytical standards by testing labs to ensure consistent drug quality.

Safety Monitoring: PvPI & MvPI

• Pharmacovigilance Programme of India (PvPI): IPC acts as the National Coordination Centre, monitoring adverse drug reactions and ensuring public safety through data collection and analysis 
• Materiovigilance Programme of India (MvPI): IPC tracks medical device-associated adverse events, ensuring device safety across the healthcare ecosystem.

Modernization & Capacity Building

• The IPC is digitizing the IP (print and online editions), launching the next edition in 2026, which will include 100+ new chemical monographs, plus updated standards for vaccines, biotech products, blood components, and excipients.
• IPC frequently conducts skill development programs and training for regulators, drug analysts, industry personnel, and academics on pharmacopoeial science and quality control. 

• IPC’s pharmacovigilance frameworks (PvPI, MvPI) ensure patient safety, supporting India’s drug regulatory authority and aligning with WHO and domestic health mandates